

# 1 **Salivary molecular testing for SARS-CoV-2: simplifying the diagnosis without losing accuracy.**

2 Francesca Saluzzo<sup>1</sup>, Paola Mantegani<sup>1</sup>, Valeria Poletti de Chaurand<sup>1</sup>, Federica Cugnata<sup>2</sup>, Patrizia Rovere-  
3 Querini<sup>3</sup>, Marta Cilla<sup>3</sup>, Patrizia Erba<sup>4</sup>, Sara Racca<sup>5</sup>, Cristina Tresoldi<sup>6</sup>, Caterina Uberti-Foppa<sup>7</sup>, Clelia Di Serio<sup>2</sup>,  
4 Daniela Maria Cirillo<sup>1</sup>.

5 1 Division of Immunology, Transplantation and Infectious Disease, IRCCS Ospedale San Raffaele - Milano (Italy),

6 2 CUSSB-University Center for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University - Milano (Italy),

7 3 IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University - Milano (Italy),

8 4 Servizio di Medicina Preventiva, IRCCS Ospedale San Raffaele - Milano (Italy),

9 5 Laboratorio Microbiologia/Virologia, SMEL, IRCCS Ospedale San Raffaele- Milano (Italy),

10 6 Molecular Hematology Unit, IRCCS Ospedale San Raffaele- Milano (Italy),

11 7 Division of Infectious Diseases, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University- Milano (Italy).

12

## 13 **Abstract**

### 14 Background

15 Quantitative RT-PCR on NasoPharyngeal Swab (NPS) is still considered the standard for the diagnosis of  
16 SARS-CoV-2 infection, even if saliva has been evaluated in several studies as a possible alternative. The use  
17 of point of care (POC) platforms, providing highly specific results performed on saliva could simplify the  
18 diagnosis of COVID-19 and contribute to contain the spreading of SARS-CoV-2.

### 19 Methods

20 We assess the sensitivity and specificity of molecular testing performed on saliva in comparison to NPS using  
21 two different POC platforms (DiaSorin Simplexa™ and Cepheid Xpert®). NPS and saliva were collected  
22 prospectively from asymptomatic health care workers and mildly symptomatic patients. Moreover, the  
23 stability of saliva samples after storage at -80°C for up to 45 days was tested.

### 24 Results

25 The obtained results in comparison to NPS demonstrated for both DiaSorin Simplexa™ and Xpert® Xpress a  
26 specificity of 100% and a sensitivity of 90.24%. The overall agreement between the tests performed on saliva  
27 was 98%. A positive correlation in Ct values detected on saliva and on NPS was identified for all the targets  
28 shared by the tests in analysis (Orf1ab, E and N2). Both S Ct values and Orf1ab Ct values were not significantly  
29 different before and after the freezing in the tested saliva samples.

### 30 Conclusion

31 The obtained results demonstrated an overall performance of saliva comparable to NPS, confirming that RT-  
32 PCR performed using POCs on saliva could represent a valid public health solution for controlling SARS-

33 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

CoV-2 pandemic.

## 34 **Introduction**

35 The possibility to rely on rapid and accurate diagnostic techniques has proved itself crucial during the last year  
36 to contain the spreading of SARS-CoV-2 infection<sup>1</sup>. Even if quantitative RT-PCR (RT-qPCR) on  
37 NasoPharyngeal Swab (NPS) is still considered the standard for the diagnosis of COVID19, saliva has been  
38 evaluated in several studies as a possible alternative to NPS and it is now extensively utilized in South Korea,  
39 Germany, and Japan<sup>2,3</sup>. Nonetheless, the use of saliva is still debated, and a rigorous standardization of the  
40 analysis protocol is deeply needed<sup>4-6</sup>. The application of point of care (POC) technologies on saliva, capable  
41 of rapidly performing high specific and sensitive molecular testing, could prove invaluable to allow the  
42 diagnosis even in challenging and remote settings, simplifying and speeding up the diagnostic process<sup>1</sup>.

## 43 **Methods**

44 To assess the sensitivity and specificity of molecular testing performed on saliva in comparison to NPS using  
45 two different POC platforms (DiaSorin Simplexa™ and Cepheid Xpert®), a total 129 individuals were  
46 enrolled into the study. Samples were collected prospectively, from January 2021 to May 2021, from 21  
47 asymptomatic health care workers, who took part to the screening campaign, and from 79 outpatients who had  
48 developed mild symptoms consistent with COVID19 up to 10 days before accessing the Preventive Medicine  
49 Unit, the COVID19 Mildly Symptomatic Outpatients Unit and the Emergency Department of San Raffaele  
50 Hospital, Milan. Moreover, samples from 29 patients, hospitalized for COVID19 in March 2020, were  
51 retrieved by San Raffaele Hospital Biobank. For each patient, a self-collected saliva sample and an NPS,  
52 collected at the same timepoint by a healthcare worker, were analysed.

53 With the exclusion of the samples collected in March 2020, that were stored at -80°C immediately after the  
54 sampling, all samples were preserved at 4°C and analysed within 24 hours from the collection. The DiaSorin  
55 Simplexa™ COVID-19 Direct tests (Simplexa™) were performed on saliva diluted 1:1 with saline as per the  
56 instruction for use, and the same condition was used off label for the Xpert® Xpress SARS-CoV-2 kit  
57 (Xpert®). NPS were analysed with Xpert® Xpress SARS-COV-2 or Roche Cobas® SARS-CoV-2 test  
58 (Cobas®), as by manufacturers' instructions.

## 59 **Results**

60 The results obtained on saliva samples collected prospectively in the first months of 2021, in comparison to  
61 NPS demonstrated for both Simplexa™ and Xpert® a specificity of 100% (95% CI: 93.94%-100%) and a  
62 sensitivity of 90.24% (95% CI: 76.87%-97.28%). The overall agreement between the two tests performed on  
63 saliva was of 98%.

64 Since the two kits employed on saliva, as well as the ones utilized on NPS, adopted different target genes  
65 (Simplexa™: Orf1ab and S; Xpert®: N2 and E; Cobas®: E and Orf1ab) an analysis to evaluate the correlation  
66 between Cycle threshold (Ct) values detected respectively on saliva and on NPS was performed only for the  
67 shared targets.

68 A positive correlation in Ct values detected on saliva and on NPS was identified for Orf1ab, detected both by  
69 Simplexa™ performed on saliva and by Cobas® on NPS (Kendall correlation = 0.7704,  $p < 0.0001$ ) as well as  
70 for E (Kendall correlation = 0.7961,  $p < 0.0001$ ) and N2 (Kendall correlation = 0.8311,  $p < 0.0001$ ), both targets  
71 of Xpert® performed on saliva and on NPS (Fig.1 A).

72 Hence, when compared to NPS, both tests on saliva freshly collected appeared to have good sensitivity and  
73 specificity as well as a positive correlation in Ct values detected for the shared targets.

74 Before proceeding to examine the samples collected in March 2020, we evaluated the effects of storage at -  
75 80°C for up to 45 days on 22 saliva samples that resulted positive for SARS-CoV-2. The samples were  
76 analysed with Simplexa™ before and after the freezing and the Ct values for the two different targets (S and  
77 Orf1ab) were compared. Both S Ct values and Orf1ab Ct values were not significantly different before  
78 (median (interquartile range): S Ct 23.8 (20.00–25.50), Orf1ab Ct 24.95 (21.38–27.52)) and after (median  
79 (interquartile range): S Ct 22.6 (20.55–25.4), Orf1ab Ct 24.5 (21.52–26.70) the freezing (Wilcoxon test  
80 0.0705).

81 Moreover, the observed difference in Ct values did not appear to be connected to the number of days for  
82 which the samples remained stored at -80 °C as a statistically significant correlation was not retrieved between  
83 the storage time and the Ct values (S: Kendall correlation  $p = 0.8206$ ; Orf1ab: Kendall correlation  $p = 0.7128$ )  
84 (Fig. 1B).

85 Nonetheless, once the saliva samples collected by the Biobank from COVID-19 inpatients in March 2020 were  
86 included in the performance analysis (data not showed), the sensitivity resulted 87.14 (95% CI: 76.99-93.95)  
87 for Simplexa™ and 91.43 (95% CI: 82.27-96.79) for Xpert®, the agreement between Simplexa™ and Xpert®  
88 performed on saliva was 96.10%.

89 Considering that the median time from illness' onset to collection of the Biobank specimens was 4 days (IQR:  
90 2-9 days) while for the samples collected in 2021 was 2.5 days (IQR: 2-4 days), the time elapsed between  
91 symptoms' onset and the samples collection was evaluated as a possible factor affecting Ct values and  
92 consequently cause the differences in specificity and sensitivity observed between the cohort of prospectively  
93 collected samples and the Biobank ones.

94 Categorizing the samples from symptomatic patients in three different categories (0-2 days from symptoms'  
95 onset to collection, 3-7 days and >7 days) for saliva samples, no statistically significant differences were  
96 observed between different timeframes in Ct values for either of the target in analysis (E: Kruskal-Wallis test  
97  $p = 0.80$ ; Orf1ab: Kruskal-Wallis test  $p = 0.39$ ; N2: Kruskal-Wallis test  $p = 0.80$ ) (Fig. 1C). Instead, NPS  
98 demonstrated an increase in Ct values, statistically significant for both E gene (Kruskal-Wallis test  $p =$   
99 0,007544) and for ORF1a/b gene (Kruskal-Wallis test  $p = 0,03605$ ).

## 100 **Conclusions**


101 Both Xpert® and Simplexa™ platforms proved themselves practical and easy to use on saliva and the obtained  
102 results demonstrated an overall performance comparable to NPS, with a specificity of 100% and a sensitivity  
103 higher than 90% for freshly collected samples and higher than 87% for the ones stored at -80°C, demonstrating  
104 the possibility to perform these tests also on frozen samples with only a minimal loss in sensitivity. It is  
105 interesting to notice that the samples contained all the different SARS-CoV-2 variants of concern currently  
106 represented in Italy, but both kits' performance was not compromised by this factor.

107 The tests employed exhibited an overall excellent level of agreement, even considering the differences  
108 identified once the Biobank samples have been included into the analysis.

109 As the pandemic evolves, the implementation of a testing strategy based on POCs widespread on the territory  
110 in a capillary manner, could help to guarantee a prompt on-site diagnosis, allowing the rapid identification and  
111 control of clusters and outbreaks, finally protecting the community from the transmission. Moreover, if this  
112 new diagnostic plan would involve the use of self-collecting highly reliable samples, as saliva, directly at  
113 patients' homes, we would reduce the burden on healthcare workers, and the costs related to the use of NPS  
114 with specific transport medium. This approach would also contribute to drastically decreasing the number of  
115 possible infective individuals moving to reach the sampling hubs, who could represent a major public health  
116 risk.

117 This diagnostic approach could be easily implemented also in Low Middle Income Countries, where POCs  
118 platforms are already widely employed for the diagnosis of other illnesses, as Tuberculosis, HIV and viral  
119 hepatitis.

120 In conclusion, our findings support the use of saliva on POCs technologies as a valid solution to simplify,  
121 speed up and widespread the diagnostic process for the control of COVID19 epidemic.



122

123 Fig 1. A) Ct values comparison between saliva (examined with Simplexa or Xpert) and NPS for different  
 124 targets (genes S, Orf1ab and E); B) Ct values before and after storage at  $-80^{\circ}\text{C}$  at different timepoints; C)  
 125 Comparison of Ct values at different time frames from symptoms' onset.

126 **Bibliography:**

127

- 128 1. Pérez-López B, Mir M. Commercialized diagnostic technologies to combat SARS-CoV2: Advantages  
129 and disadvantages. *Talanta*. 2021 Apr 1;225:121898.
- 130
- 131 2. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard sample for SARS-  
132 CoV-2 detection. *Lancet Respir Med*. 2021 Apr 19:S2213-2600(21)00178-8. doi: 10.1016/S2213-  
133 2600(21)00178-8.
- 134
- 135 3. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren  
136 JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-  
137 Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez  
138 J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M,  
139 Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S,  
140 Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko AI.  
141 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N Engl J Med*. 2020 Sep  
142 24;383(13):1283-1286.
- 143
- 144 4. Kapoor P, Chowdhry A, Kharbanda OP, Bablani Popli D, Gautam K, Saini V. Exploring salivary  
145 diagnostics in COVID-19: a scoping review and research suggestions. *BDJ Open*. 2021 Jan 26;7(1):8.
- 146
- 147 5. McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, Molberg K, Cavuoti D.  
148 Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using  
149 Cepheid Xpert Xpress SARS-CoV-2. *J Clin Microbiol*. 2020 Jul 23;58(8):e01109-20.
- 150
- 151 6. Wong RC, Wong AH, Ho YI, Leung EC, Lai RW. Evaluation on testing of deep throat saliva and  
152 lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay. *J Clin Virol*. 2020  
153 Oct;131:104593.

154

155